The Healthspan Arms Race

By Nicholas Thomas | TrendyVest A version of the longevity story is almost irresistible. A laboratory discovers the mechanism that makes us old. A drug interrupts it.

Human beings suddenly live dramatically longer. It makes for a wonderful headline. It probably isn't also how the first meaningful extension of human healthspan will happen.

The more interesting version is already unfolding, and it looks considerably less like science fiction. It looks like obesity drugs that also reduce cardiovascular risk. Cholesterol medicines, simple enough to take every morning.

Treatments that intervene earlier in cancer. Drugs aimed at chronic inflammation, kidney disease and hypertension. Medicines that make diseases easier to control before years of accumulated damage become irreversible.

None of these medicines “cures aging.” Together, however, they point toward something that could matter far more over the next decade: turning more of the diseases that make old age unhealthy into conditions that can be prevented, delayed or controlled much earlier. And some of the world's largest pharmaceutical companies are beginning to converge on that opportunity. Eli Lilly, Novo Nordisk, Johnson & Johnson, Merck and AstraZeneca are approaching it from remarkably different directions.

Lilly and Novo are attempting to turn obesity treatment into broad cardiometabolic medicine. Merck is trying to extend prevention deeper into cardiovascular disease while rebuilding beyond Keytruda. AstraZeneca is assembling a portfolio across blood pressure, kidney disease, metabolism, and cancer.

Johnson & Johnson is betting heavily on immune disease, precision oncology and new ways of delivering medicines. Look at each pipeline separately, and you see five pharmaceutical strategies. Look at them together and something else becomes visible.

The pharmaceutical industry is beginning to compete over the biology that determines how we age. That is the healthspan arms race. The obesity drug was only the beginning.

Eli Lilly provides perhaps the clearest example of how quickly a drug's definition can change. Tirzepatide began as a diabetes and weight-loss story. Then obesity medicine started colliding with sleep apnea, cardiovascular disease, osteoarthritis, and other conditions that frequently travel with excess weight.

Now Lilly is developing retatrutide. Retatrutide activates three hormone receptors—GIP, GLP-1 and glucagon—and its Phase III results have been extraordinary. In TRIUMPH-1, participants receiving the 12-milligram dose lost an average of 28.3% of their body weight at 80 weeks.

Among participants with a baseline BMI of at least 35 who continued into an extension, average weight loss reached 30.3% at 104 weeks. Those numbers alone would make retatrutide one of the most closely watched medicines in the industry. But weight loss may not be the most important part of the story.

Lilly also reported substantial improvements in knee osteoarthritis pain and obstructive sleep apnea. In additional Phase III studies announced in July, people with obesity or overweight and type 2 diabetes lost as much as 20.8% of their body weight, while participants with severe obesity and established cardiovascular disease lost as much as 22.6%. Lilly says it now has the clinical package to support global regulatory submissions for obesity, obstructive sleep apnea and knee osteoarthritis pain, with a U.S. filing planned for the first quarter of 2027.

That begins to change how we should think about the obesity market. The eventual product may not simply be a “weight-loss drug.” It may be a platform for treating several diseases that share obesity as an upstream risk factor. That distinction matters enormously for healthspan.

If a therapy helps someone lose substantial excess weight but also improves glycemic control, reduces sleep apnea and relieves load on damaged joints, the medical value isn’t confined to what the scale says. It potentially changes several pathways through which middle age becomes chronic disease. And Lilly’s existing business is already giving it extraordinary resources to pursue that opportunity.

Second-quarter 2026 revenue increased 48% to $23 billion, driven primarily by Mounjaro and Zepbound, and Lilly raised full-year revenue guidance to $85–87 billion. The obesity franchise is financing the next obesity franchise. That is a formidable flywheel.

Novo Nordisk has a different problem. Novo helped create this market. Now it has to prove that the market doesn’t leave it behind.

That makes Novo one of the more interesting companies in the group because its position combines enormous scientific credibility with considerably greater competitive pressure. Wegovy and Ozempic established semaglutide as one of the defining medicines of this pharmaceutical cycle. More importantly, Novo has spent years accumulating evidence that GLP-1 therapy reaches beyond body weight and glucose.

Its semaglutide portfolio now stretches across obesity, diabetes, cardiovascular risk, kidney disease, and MASH. Novo is presenting additional 2026 evidence spanning that cardiometabolic spectrum, including the Wegovy pill and higher-dose Wegovy. The next act aims to move beyond GLP-1 alone.

CagriSema combines semaglutide with the amylin analog cagrilintide. Novo also has zenagamtide and other amylin-oriented programs advancing through development, while CagriSema remains scheduled for a U.S. regulatory decision in the fourth quarter of 2026. That tells us something important about where obesity pharmacology is heading.

The industry is moving from: Can we make people lose meaningful weight? toward: Can we control appetite, metabolism, body composition and cardiometabolic risk more precisely—and can we give different patients different tools? The future may not belong to one universal injection. It may look more like a therapeutic toolbox: oral medicines, injections, combinations, higher-potency therapies, maintenance regimens, and drugs selected according to the patient’s metabolic disease rather than simply their BMI.

That could make the obesity market much larger and much more segmented than today’s “Wegovy versus Zepbound” framing suggests. And it may eventually turn obesity treatment into something closer to cardiovascular prevention. Merck may have the most underrated healthspan drug in the group.

Merck’s most famous medicine is Keytruda. The medicine that may say more about the future of preventive healthcare is considerably less glamorous. It is a cholesterol pill.

In July, the FDA approved Merck’s LIPFENDRA, or enlicitide, making it the first FDA-approved once-daily oral PCSK9 inhibitor for lowering LDL cholesterol in adults with hypercholesterolemia. In Phase III trials, it reduced LDL cholesterol by approximately 56% to 59% versus placebo at 24 weeks, depending on the population studied. PCSK9 itself isn’t new.

Injectable PCSK9 therapies have demonstrated that the biological pathway can produce powerful LDL reductions. What changes with enlicitide is the delivery mechanism. A pill is easier to distribute than an injection.

That sounds almost mundane compared with a triple agonist producing weight loss approaching bariatric-surgery territory. It isn’t. One of medicine's great unsolved problems isn't discovering treatments that work.

It is getting enormous numbers of people to use effective treatments consistently enough, early enough, for decades. Cardiovascular disease develops over time. LDL exposure accumulates.

Blood pressure accumulates. Metabolic dysfunction accumulates. Healthspan is partly a problem of cumulative biological damage.

A powerful oral therapy that makes aggressive LDL lowering easier to prescribe and easier to accept could therefore matter far beyond the excitement normally attached to a new cholesterol medicine. Merck is simultaneously rebuilding its pipeline beyond Keytruda. The company has identified more than 20 new growth drivers, with large opportunities across oncology, cardiometabolic and respiratory disease, infectious disease, immunology and ophthalmology.

Its internal commercial estimates—company projections rather than guaranteed outcomes—place the non-risk-adjusted opportunity from those new drivers at roughly $70 billion annually by the mid-2030s. One of those programs, tulisokibart, also deserves attention. In June, Merck reported that the anti-TL1A antibody met its primary and key secondary endpoints in a Phase III ulcerative colitis induction study.

TL1A is interesting partly because it is connected to inflammatory and fibrotic biology, giving Merck another potential foothold in chronic diseases that progressively damage tissue over time. Merck’s healthspan strategy may therefore be less obvious than Lilly’s. But it may ultimately be just as important: reduce accumulated cardiovascular risk, control chronic inflammation and replace the revenue cliff created by one of the most successful cancer drugs ever developed.

AstraZeneca is attacking the quiet killer. If Lilly’s story is obesity and Merck’s is partly cholesterol, AstraZeneca may have one of the most underappreciated targets in the entire healthspan conversation. Blood pressure.

In May, the FDA approved AstraZeneca’s Baxfendy, or baxdrostat, as the first aldosterone synthase inhibitor for adults whose hypertension remains inadequately controlled despite treatment. There is nothing fashionable about hypertension. There is also almost nothing more relevant to healthy aging.

AstraZeneca notes that roughly 1.4 billion people worldwide live with hypertension, and elevated blood pressure remains one of the world’s most consequential modifiable cardiovascular risk factors. This is what makes the healthspan framing useful. A drug doesn’t need to interact with an “aging gene” to affect how someone ages.

Prevent a stroke at 68. Delay kidney failure. Reduce heart failure.

Prevent years of vascular injury. Those outcomes can matter enormously to how many years a person remains independent and healthy. AstraZeneca is also moving into obesity.

Its oral GLP-1 candidate, elecoglipron, produced 11.8% average weight loss at 36 weeks at the highest studied dose in its Phase IIb obesity trial and reduced HbA1c by 1.9 percentage points at 26 weeks in a separate type 2 diabetes study. The company has moved the drug into a broad Phase III program that includes cardiovascular and kidney outcomes. That last part is worth emphasizing.

The obesity race is already beginning to move beyond weight. Companies increasingly want to demonstrate that these medicines alter the diseases associated with obesity. AstraZeneca’s pipeline reinforces the point: beyond elecoglipron and baxdrostat, its cardiovascular, renal and metabolism portfolio includes programs in chronic kidney disease, dyslipidemia, heart failure, MASH and additional obesity combinations.

This is less a collection of unrelated drugs than an attempt to surround cardiometabolic aging from multiple directions. Johnson & Johnson may be making the broadest bet. Johnson & Johnson is harder to summarize because it isn’t making one concentrated healthspan wager.

That may be the point. J&J’s pipeline spans oncology, immunology, neuroscience and cardiovascular disease, with several assets that the company believes could eventually exceed $5 billion in peak-year sales. Those are management estimates, not forecasts we should treat as certain, but the breadth is notable.

One of the most interesting recent examples is ICOTYDE, or icotrokinra. The FDA approved the once-daily oral targeted peptide in March for moderate-to-severe plaque psoriasis. It is the first approved oral peptide specifically targeting the IL-23 receptor, attempting to deliver targeted immune biology in the convenience of a pill.

That could become important beyond psoriasis if the platform succeeds across autoimmune diseases. Then there is J&J’s approach to cancer. INLEXZO doesn’t simply introduce another molecule.

It changes where and how the drug is delivered. The system sits inside the bladder and continuously releases gemcitabine locally. In the population supporting its U.S. approval, J&J reported an 82% complete-response rate, offering some patients with difficult non-muscle-invasive bladder cancer another option before bladder removal.

That is a different kind of pharmaceutical innovation. Instead of asking only, What molecule should we invent?, the question becomes: Can we put an existing therapeutic exactly where it needs to be, for exactly as long as it needs to be there? That may eventually become an important part of precision medicine.

Cancer itself is beginning to move earlier. AstraZeneca’s recent work in breast cancer illustrates another change that could matter profoundly to healthspan. Traditional oncology often waits until imaging demonstrates that a tumor has progressed and then changes treatment.

The SERENA-6 strategy did something different. Researchers monitored circulating tumor DNA for an emerging ESR1 mutation and switched endocrine therapy when that molecular signal appeared—before radiographic disease progression. In the trial, switching to camizestrant plus a CDK4/6 inhibitor reduced the risk of disease progression or death by more than half relative to remaining on standard therapy.

The approach has since received approvals in Europe and, in September, accelerated approval in the United States for the specified ESR1-mutated setting. That is potentially more important than one breast-cancer drug. It hints at a different model of medicine: detect biological escape before conventional symptoms or imaging show failure, then intervene while the disease is still easier to control.

Not every attempt will work. AstraZeneca’s separate SERENA-4 trial recently failed its primary progression-free-survival endpoint in a broader first-line population, an important reminder not to extrapolate a precision strategy beyond the population in which it has actually demonstrated benefit. But the concept remains powerful.

The earlier medicine can identify deterioration, the more opportunity it may have to prevent irreversible damage. And that principle applies far beyond cancer. The hidden competition isn’t weight loss.

This is where the five companies begin to converge. Lilly is attacking obesity and its downstream complications. Novo is trying to turn incretin medicine into broad cardiometabolic disease management.

Merck is making potent cholesterol reduction easier while expanding into inflammatory disease. AstraZeneca is focusing on hypertension, kidney disease, obesity, and cardiovascular risk. Johnson & Johnson is developing targeted immune therapies, precision cancer treatments and new delivery systems.

On the surface, those businesses look different. Underneath them is the same objective: move treatment upstream. Treat obesity before diabetes and cardiovascular disease accumulate.

Treat LDL before decades of plaque become a heart attack. Treat hypertension before vascular injury becomes stroke, kidney failure, or heart failure. Detect cancer evolution before conventional progression becomes visible.

Control chronic inflammation before repeated injury becomes permanent structural damage. That is what the first real healthspan revolution may look like. Not immortality.

Not a single pill for aging. Less accumulated damage. The metric medicine has been missing.

We currently measure pharmaceutical success disease by disease. How much did LDL fall? How much weight was lost?

How much longer until the tumor progressed? How much did blood pressure decline? Those endpoints are necessary because clinical trials need measurable outcomes.

But human beings don’t experience aging one endpoint at a time. A 58-year-old patient may simultaneously carry excess visceral fat, elevated blood pressure, insulin resistance, high LDL, sleep apnea, and early kidney dysfunction. Treating one condition may influence several others.

This suggests that the most valuable medicines of the next decade could increasingly be judged by something broader than their original indication: How many years of serious chronic disease can they prevent or postpone? We don’t yet have a clean financial or clinical metric for that. Perhaps we eventually will.

Call it healthy-years preserved. If medicine begins measuring interventions that way, some drugs we currently describe as obesity drugs, cholesterol drugs, or blood-pressure drugs may eventually be understood differently. They are interventions against the accumulation of damage.

There is another arms race hiding underneath the drugs. The companies that succeed may not be the ones with the most effective molecules. They may be the ones that build the best feedback systems around patients.

Continuous glucose monitors already show what happens when medicine gains persistent data instead of occasional snapshots. Now imagine that principle expanding. Blood pressure.

Sleep. Cardiac rhythm. Body composition.

Kidney function. Inflammatory markers. Genomics.

Proteomics. Circulating tumor DNA. Medication adherence.

AI-assisted interpretation. The pharmaceutical company of the future may not merely sell a medicine and wait three months for the patient to return to a physician. The treatment could exist inside a continuous loop: measure → predict → intervene → measure again.

That would begin to resemble what technology companies call a closed-loop system. And it could become extraordinarily valuable because the company would no longer be selling only a molecule. It would be participating in managing health over time.

Which company is actually furthest ahead? There isn’t one answer because the five companies are solving different pieces of the problem. Lilly currently has perhaps the most dramatic clinical program in cardiometabolic medicine.

Retatrutide’s Phase III weight-loss results are remarkable, and the potential to simultaneously affect obesity, diabetes, sleep apnea, and osteoarthritis makes the program unusually broad. Novo has accumulated perhaps the deepest real-world and outcomes experience in modern incretin medicine and is trying to expand that franchise across cardiovascular, kidney, liver and next-generation amylin biology. Merck’s oral PCSK9 inhibitor could be less visually spectacular but extremely important if oral delivery materially expands long-term use of powerful LDL reduction.

AstraZeneca has built an unusually broad attack on cardiomet